|
Today, the Centers for Medicare & Medicaid Services (CMS)
released a State Medicaid Director Letter (SMDL) that provides states and
territories with information on changes to the Medicaid benefit package
implemented by the Consolidated Appropriations Act, 2021 (CAA). The CAA
added a new mandatory benefit for coverage of routine patient costs for
services furnished in connection with participation by Medicaid
beneficiaries in qualifying clinical trials, on or after January 1, 2022.
The guidance provides important information to states about
these legislative changes, including how to incorporate them into the
Medicaid State Plan.
Learn more here: https://www.medicaid.gov/federal-policy-guidance/downloads/smd21005.pdf
|
No comments:
Post a Comment